Background. High-flow nasal oxygen therapy (HFNOT) therapy has been increasingly used in patients with acute hypoxemic (Type I) respiratory failure (RF). Meanwhile indications and clinical effectiveness of HFNOT in patients with hypercapnic (Type II) RF remain controversial. The aim of our study was to evaluate the outcomes of primary HFTNOT in patients with hypoxemic and hypercapnic RF.
INTRODUCTION
High-flow nasal oxygen therapy (HFNOT) delivers warm and humidified oxygen through a nasal cannulas with a high flow rate (up to 60 L/min) and facilitates increase in the fraction of inspired oxygen (FiO 2 ) to 1.0 (100%) (1) . A number of physiological benefits, such as humidification, reduced anatomical dead space, positive end-expiratory pressure effect, and fewer restrictions on food intake or communication makes HFNOT tolerable for a longer therapeutic period (2, 3) and superior in comparison with conventional non-invasive ventilation (NIV). Despite multiple beneficial effects of HFNOT, research data is controversial. Recent meta-analysis failed to prove different intubation and mortality rates compared with standard oxygen therapy or NIV in patients with acute hypoxemic respiratory failure (4) . In patients with hypercapnia, NIV is still recognized as the first-line intervention. However, several recent studies suggested that HFNOT is effective in patients with carbon dioxide retention, and demonstrated improvement in ventilatory parameters (5, 6) .
The aim of this study was to investigate the feasibility of the use of HFNC oxygen therapy in patients with acute pneumonia-related respiratory failure and to compare primary and secondary outcomes in hypoxemic (Type I) and hypercapnic (Type II) respiratory failure.
MATERIALS AND METHODS
This retrospective observational study included patients admitted to the intensive care of tertiary university hospital, diagnosed with severe community acquired pneumonia (CAP) and started on HFNOT due to progressively worsening respiratory failure. Exclusion criteria were: severe hemodynamic instability and use of vasopressors, a Glasgow Coma Scale score of 12 points or less (on a scale of 3 to 15, with lower scores indicating reduced levels of consciousness), contraindication to NIV, urgent need for endotracheal intubation, and a do-not-intubate order. Patients were defined as having (1) and PaCO 2 one and six hours before and after HFNOT intervention. The primary end-point was intubation rate after HFNOT. The secondary endpoint was the 30-day mortality after an admission regardless of the cause.
Statistical analysis
Excel software was used for initial data collation and Statistical Package of Social Sciences (SPSS v.15) was used for statistical analysis. Demographic data were expressed as mean ± standard deviation, and dichotomous variables were reported as number (percentage).
RESULTS
Fifty one (n = 51) patients were included in the final analysis: 32 (63%) were diagnosed with Type I RF and 19 (37%) with moderate hypercapnic respiratory failure and were qualified as Type 2. Changes in clinical and arterial blood gas analysis are presented in the Table. The mean age was 51.6 ± 9.5 and 68.1 ± 7.8 years in Type I and Type II groups, respectively. After one hour of HFNOT there was an improvement of oxygen saturation in Type I RF patients (from 94.8 to 95.03%) and an increase in PaO 2 /FiO 2 ration from 181 to 191 mmHg. In type II RF patients, PaCO 2 levels improved from 56.4 to 54.9 mmHg and PaO 2 /FiO 2 improved from 193.6 to 209.9 mmHg.
Within six hours of HFNT therapy we observed a further increase in PaO 2 /FiO 2 ration in both groups to 182.3 and 223.9 mmHg, respectively. Escalation to non-invasive ventilation was required in four (8%) patients in Type I RF group and seven (14%) in Type II group. Three and one patient were intubated in each group, respectively. There were no mortalities in either of the groups.
DISCUSSION
We investigated the effectiveness of HFNOT in patients with acute Type I and Type II respiratory failure. Type I, or hypoxemic, failure is commonly seen in pulmonary oedema or pneumonia, where lung tissue itself is damaged. Meanwhile, Type II respiratory failure is multifactorial and caused by alveolar hypo-ventilation or insufficient excretion of the CO 2 that is being produced. Hypoxaemia resulting from ventilation/perfusion abnormalities or impaired diffusion can easily be corrected by supplementing inspired oxygen, whereas in hypercapnic patients, generally more than one factor contributes to the rise in PaCO 2 (7) . NF-NOT might be effective in hypercapnic respiratory failure due to its physiological effect of CO 2 washout from the anatomical dead space, with resulting increase in ventilatory efficiency (8, 9) . In addition, positive airway pressures result in improvement of ventilation and perfusion matching and a reduction in respiratory workload. Despite numerous HFNOT advantages for patients who cannot tolerate or fail standard NIV, there are no established guidelines for the use of high flow oxygen in hypercapnic respiratory failure. Our data confirmed that HFNOT might be beneficial not only in hypoxemic but in acute hypercapnic respiratory failure as well. We have observed increase of Pa/FiO 2 ratio alongside with clinically improving symptoms of hypoxemia in Type I respiratory failure. In patients with Type II respiratory failure, improvement of hypercapnia was achieved after 1 hour of HFNOT. Similar effects of HFNOT have been reported in cases with acute respiratory failure with CO 2 retention (10, 11). Our findings were similar to recent study data providing the evidence that HFNOT have similar escalation to intubation rates to NIV (12, 13) . Most of the authors agree that in the light of conflicting heterogenous data clear criteria for respiratory support escalation are necessary and mechanical ventilation should not be delayed if appropriate oxygenation goals are not obtained with HFNOT support. More evidence of HFNOT versus other forms of non-invasive positive-pressure ventilation is needed to establish recommendations and guidelines. Išvados. Tyrimo duomenimis, DTDT gali būti efektyviai naudojama I ir II tipų kvėpavimo nepakankamumo atvejais. Būtina laiku įvertinti pacientų, kuriems būtini kiti ventiliacijos būdai, būkles. Veiksnius, susijusius su nesėkminga DTDT, būtina identifikuoti atliekant didesnės apimties tyrimus.
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